This is a multi-disciplinary collaborative research project directed toward the development of more effective methods of treatment of human cancer in all its forms. Included in this project are the following programs: 1) the exploration of new therapeutic agents through a wide range of neoplastic diseases in Phase II and Phase III studies, and the coincident study of the toxicities of these agents; 2) the exploration of new combinations of new and old agents in an effort to exploit synergistic combinations more effectively; 3) the development of multi-modal approaches to specific tumor problems using surgical, immuological and radio- therapeutic measure in optimal combinations; 4) the involvement of pertinent basic science disciplines such as biochemistry, pharmacology, cellular biology and mathematics in the formulation and execution of specific treatment protocols; 5) improvement of cancer care in the community at large by using these programs in the educational effort directed at pre- and post-doctoral students, nurses, allied medical personnel and physicians. This research effort will be conducted in cooperation with clinical and basic science investigators at other SWOG institutions and the NCI whose collective experience, information and wisdom will be used to design and conduct clinical trials which will answer important questions in the therapy of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA004920-31
Application #
3555838
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1984-01-01
Project End
1992-12-31
Budget Start
1990-01-01
Budget End
1990-12-31
Support Year
31
Fiscal Year
1990
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Harigopal, Malini; Barlow, William E; Tedeschi, Greg et al. (2010) Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Tubbs, Raymond; Barlow, William E; Budd, G Thomas et al. (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881-6
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Swanson, Gregory P; Goldman, Bryan; Tangen, Catherine M et al. (2008) The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol 180:2453-7;discussion 2458
Sartor, A Oliver; Tangen, Catherine M; Hussain, Maha H A et al. (2008) Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 112:2393-400
Moinpour, Carol M; Hayden, Katherine A; Unger, Joseph M et al. (2008) Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 26:112-20
Swinnen, Lode J; Rankin, Cathryn; Carraway, Hetty et al. (2008) A phase II study of cisplatin preceded by a 12-h continuous infusion of concurrent hydroxyurea and cytosine arabinoside (Ara-C) for adult patients with malignant gliomas (Southwest Oncology Group S9149). J Neurooncol 86:353-8
Thompson, John A; Fisher, Richard I; Leblanc, Michael et al. (2008) Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz Blood 111:4048-54

Showing the most recent 10 out of 136 publications